<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2384">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01555983</url>
  </required_header>
  <id_info>
    <org_study_id>256412-3</org_study_id>
    <secondary_id>1R01DA030424-01A1</secondary_id>
    <nct_id>NCT01555983</nct_id>
  </id_info>
  <brief_title>Vaporized Cannabis and Spinal Cord Injury Pain</brief_title>
  <official_title>The Effect of Vaporized Cannabis on Neuropathic Pain in Spinal Cord Injury</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Barth Wilsey</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>VA Northern California Health Care System</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California, San Diego</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Davis</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will demonstrate that vaporized marijuana results in antinociception when
      compared to placebo in subjects with spinal cord injury. To further evaluate potential
      benefits and side effects, the effect of different strengths of cannabis on mood, cognition,
      and psychomotor performance will also be measured.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will demonstrate that vaporized cannabis can produce antinociceptive effects
      compared to placebo in human subjects with spinal cord injury (SCI). A within-subject
      crossover study of the effects of cannabis versus placebo on spontaneous and evoked pain
      will be performed. A synopsis of antinociception with mood, cognitive impairment,
      psychomotor performance, and side effects will be obtained to help evaluate the utility of
      vaporized marijuana in SCI neuropathic pain.

      This study will compare the analgesic and side effect profile of low (3.5%) to high dose
      (7.0%) delta 9-tetrahydrocannabinol in subjects with spinal cord injury pain. It is
      hypothesized that a low dose will produce a lesser degree of neuropsychological impairment
      while maintaining a similar degree of pain relief to the higher dose. The use of two
      different strengths will help determine tolerable dosing for the treatment of SCI
      neuropathic pain.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number of Participants Achieving a Reduction in Pain Intensity of 30% or More</measure>
    <time_frame>hourly pain assessments for 8 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of participants achieving a reduction of pain intensity of 30% or more, a level believed to be clinically important, was estimated for each treatment dose.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Spinal Cord Injuries</condition>
  <condition>Spinal Cord Diseases</condition>
  <arm_group>
    <arm_group_label>Vaporization of Cannabis 6.7% THC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Inhaling of standardized measured puffs of Vaporized High Dose 6.7% THC. Monitored for 8 hours measuring psychoactive and analgesic effects.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vaporization of Cannabis 2.9% THC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Inhaling standardized measured puffs of Vaporized Low Dose 2.9% THC. Monitored for 8 hours measuring psychoactive and analgesic effects.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vaporization of Cannabis Placebo THC</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Inhaling standardized measured puffs of Placebo THC. Monitored for 8 hours measuring psychoactive and analgesic effects.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vaporization of Cannabis</intervention_name>
    <description>Randomized, Controlled Crossover Trial of Vaporized Cannabis using different strengths of THC in patients with Central Neuropathic Pain Active Comparator: Vaporized High Dose 6.7% THC Active Comparator: Vaporized High Dose 2.9% THC Placebo Comparator: Vaporized Placebo THC</description>
    <arm_group_label>Vaporization of Cannabis 6.7% THC</arm_group_label>
    <arm_group_label>Vaporization of Cannabis 2.9% THC</arm_group_label>
    <arm_group_label>Vaporization of Cannabis Placebo THC</arm_group_label>
    <other_name>Medical Marijuana</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age greater than 18 and less than 70

          2. Pain intensity ≥ 4/10

          3. Neuropathic pain defined as chronic pain in an area of sensory abnormality
             corresponding to the spinal cord or nerve root lesion, and the pain should have no
             primary relation to movement, inflammation or other local tissue damage

          4. Leeds Assessment of Neuropathic Symptoms and Signs score greater than or equal to 12

          5. Spinal cord injury of 3 or more months duration (to avoid spontaneous recovery
             obfuscating generalizability)

        Exclusion Criteria:

          1. Known concomitant cerebral damage/cognitive impairment (TBI, Alzheimer's Disease
             Vascular dementia, Parkinson's disease, dementia with Lewy Bodies and Front temporal
             dementia

          2. Clinically significant or unstable medical condition (i.e., cardiac, respiratory,
             hepatic or renal disease) that, in the opinion of the investigator, would compromise
             participation in the study

          3. Neurologic disorders unrelated to spinal cord injury that may confound the assessment
             of the central neuropathic pain due to spinal cord injury (hereditary neuropathies;
             diabetic peripheral neuropathy; traumatic neuropathy; and immune-mediated
             neuropathies)

          4. Active substance abuse within past year using &quot;The Substance Abuse Module of
             Diagnostic Interview Schedule for DSM-IV

          5. Pregnancy as ascertained by a self-report and a mandatory commercial pregnancy test

          6. Currently on probation or parole.

          7. Hx of Schizophrenia, Bipolar Depression with Mania, current suicidal ideation or past
             history of suicide attempt 8. Severe depression (Patient Health Questionnaire-9 ≥ 15)
             9. Current suicidal ideation
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barth Wilsey, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Davis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UC Davis CTSC Clinical Research Center , Sacramento VA Medical Center</name>
      <address>
        <city>Mather</city>
        <state>California</state>
        <zip>95655</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Wilsey B, Marcotte T, Tsodikov A, Millman J, Bentley H, Gouaux B, Fishman S. A randomized, placebo-controlled, crossover trial of cannabis cigarettes in neuropathic pain. J Pain. 2008 Jun;9(6):506-21. doi: 10.1016/j.jpain.2007.12.010. Epub 2008 Apr 10.</citation>
    <PMID>18403272</PMID>
  </reference>
  <reference>
    <citation>Abrams DI, Jay CA, Shade SB, Vizoso H, Reda H, Press S, Kelly ME, Rowbotham MC, Petersen KL. Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial. Neurology. 2007 Feb 13;68(7):515-21.</citation>
    <PMID>17296917</PMID>
  </reference>
  <reference>
    <citation>Abrams DI, Vizoso HP, Shade SB, Jay C, Kelly ME, Benowitz NL. Vaporization as a smokeless cannabis delivery system: a pilot study. Clin Pharmacol Ther. 2007 Nov;82(5):572-8. Epub 2007 Apr 11.</citation>
    <PMID>17429350</PMID>
  </reference>
  <reference>
    <citation>Ellis RJ, Toperoff W, Vaida F, van den Brande G, Gonzales J, Gouaux B, Bentley H, Atkinson JH. Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial. Neuropsychopharmacology. 2009 Feb;34(3):672-80. doi: 10.1038/npp.2008.120. Epub 2008 Aug 6.</citation>
    <PMID>18688212</PMID>
  </reference>
  <reference>
    <citation>Wallace M, Schulteis G, Atkinson JH, Wolfson T, Lazzaretto D, Bentley H, Gouaux B, Abramson I. Dose-dependent effects of smoked cannabis on capsaicin-induced pain and hyperalgesia in healthy volunteers. Anesthesiology. 2007 Nov;107(5):785-96.</citation>
    <PMID>18073554</PMID>
  </reference>
  <verification_date>January 2016</verification_date>
  <lastchanged_date>January 13, 2016</lastchanged_date>
  <firstreceived_date>February 9, 2012</firstreceived_date>
  <firstreceived_results_date>December 3, 2015</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Davis</investigator_affiliation>
    <investigator_full_name>Barth Wilsey</investigator_full_name>
    <investigator_title>Research Professor</investigator_title>
  </responsible_party>
  <keyword>cannabis</keyword>
  <keyword>central neuropathic pain</keyword>
  <keyword>analgesia</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Spinal Cord Diseases</mesh_term>
    <mesh_term>Spinal Cord Injuries</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled via recruitment from the UC Davis Medical Center Spinal Cord Injury Clinic, IRB-approved recruitment letters and newspaper advertisements.</recruitment_details>
      <pre_assignment_details>Screening for inclusion criteria (e.g., age &gt; 18 and ≤ 70, pain intensity ≥ 4/10 and Leeds Assessment of Neuropathic Symptoms and Signs, a pain scale based on analysis of sensory description and bedside examination of sensory dysfunction. A threshold of ≥12 on this instrument was utilized to substantiate neuropathic pain.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo First, Then 2.9%THC, Then 6.7% THC</title>
          <description>Placebo in am of first intervention visit, 2.9%THC in am of second intervention visit (after 3-10 day washout period) and then 6.7%THC in am of third intervention visit (after 3-10 day washout period).</description>
        </group>
        <group group_id="P2">
          <title>Placebo First, Then 6.7%THC, Then 2.9%THC</title>
          <description>Placebo in am of first intervention visit, 6.7%THC in am of second intervention visit (after 3-10 day washout period) and then 2.9%THC in am of third intervention visit (after 3-10 day washout period).</description>
        </group>
        <group group_id="P3">
          <title>2.9%THC First, Then Placebo, Then 6.7%THC</title>
          <description>2.9%THC in am of first intervention visit, placebo in am of second intervention visit (after 3-10 day washout period) and then 6.7%THC am of third intervention visit (after 3-10 day washout period)</description>
        </group>
        <group group_id="P4">
          <title>2.9%THC First, Then 6.7%THC, Then Placebo</title>
          <description>2.9%THC in am of first intervention visit, then 6.7%THC in am of second intervention visit (after 3-10 day washout period) and then placebo in am of third intervention visit (after 3-10 day washout period).</description>
        </group>
        <group group_id="P5">
          <title>6.7%THC First, Then Placebo, Then 2.9%THC</title>
          <description>6.7%THC in am of first intervention visit, then placebo in am of second intervention visit (after 3-10 day washout period) and then 2.9%THC in am of third intervention visit (after 3-10 day washout period).</description>
        </group>
        <group group_id="P6">
          <title>6.7%THC First, Then 2.9%THC, Then Placebo</title>
          <description>6.7%THC in am of first intervention visit, then 2.9%THC in am of second intervention visit (after 3-10 day washout period) and then placebo in am of third intervention visit (after 3-10 day washout period).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8">One subject only finished the placebo session, then dropped out of study</participants>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="4">One subject complete 6.7%THC and placebo sessions, then dropped out</participants>
                <participants group_id="P6" count="6">One subject completed the 6.7%THC session, then dropped out.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Consented subjects with at least one study visit</population>
      <group_list>
        <group group_id="B1">
          <title>All Study Participants</title>
          <description>All participants received all interventions</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="42"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="46.4" spread="13.6"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="13"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="29"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="42"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Achieving a Reduction in Pain Intensity of 30% or More</title>
        <description>Number of participants achieving a reduction of pain intensity of 30% or more, a level believed to be clinically important, was estimated for each treatment dose.</description>
        <time_frame>hourly pain assessments for 8 hours</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Placebo THC</title>
            <description>Session at which placebo THC was administered</description>
          </group>
          <group group_id="O2">
            <title>2.9% THC</title>
            <description>Vaporization of Cannabis 2.9% THC</description>
          </group>
          <group group_id="O3">
            <title>6.7% THC</title>
            <description>Vaporization of Cannabis 6.7% THC</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="41"/>
                  <measurement group_id="O2" value="38"/>
                  <measurement group_id="O3" value="41"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants Achieving a Reduction in Pain Intensity of 30% or More</title>
            <description>Number of participants achieving a reduction of pain intensity of 30% or more, a level believed to be clinically important, was estimated for each treatment dose.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="18"/>
                  <measurement group_id="O2" value="26"/>
                  <measurement group_id="O3" value="35"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The number needed to treat (NNT) to achieve 30% pain reduction during the 8-hour period was 4 (95% CI: 2.1-25.3) for the lower dose vs. placebo, and 3 (95% CI: 1.6-4.2) for the higher dose versus placebo.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;.05</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Cochran-Armitage trend tes</param_type>
            <param_value>.0001</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo THC</title>
          <description>Vaporization of Cannabis Placebo THC</description>
        </group>
        <group group_id="E2">
          <title>2.9% THC</title>
          <description>Vaporization of Cannabis 2.9% THC</description>
        </group>
        <group group_id="E3">
          <title>6.7% THC</title>
          <description>Vaporization of Cannabis 6.7% THC</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>low blood pressure</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>orthostatic hypotension</sub_title>
                <description>Patient had orthostatic hypotension. Symptomatically, he stated he was going to &quot;pass out&quot; and the the room went dark. BP initially unobtainable but returned to baseline with assuming supine position.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Barth Wilsey MD</name_or_title>
      <organization>UC Davis (currently at UC San Diego)</organization>
      <phone>916-402-2270</phone>
      <email>bwilsey@ucsd.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
